Glycoproteomics in neurodegenerative diseases
Citations Over TimeTop 10% of 2009 papers
Abstract
Protein glycosylation regulates protein function and cellular distribution. Additionally, aberrant protein glycosylations have been recognized to play major roles in human disorders, including neurodegenerative diseases. Glycoproteomics, a branch of proteomics that catalogs and quantifies glycoproteins, provides a powerful means to systematically profile the glycopeptides or glycoproteins of a complex mixture that are highly enriched in body fluids, and therefore, carry great potential to be diagnostic and/or prognostic markers. Application of this mass spectrometry-based technology to the study of neurodegenerative disorders (e.g., Alzheimer's disease and Parkinson's disease) is relatively new, and is expected to provide insight into the biochemical pathogenesis of neurodegeneration, as well as biomarker discovery. In this review, we have summarized the current understanding of glycoproteins in biology and neurodegenerative disease, and have discussed existing proteomic technologies that are utilized to characterize glycoproteins. Some of the ongoing studies, where glycoproteins isolated from cerebrospinal fluid and human brain are being characterized in Parkinson's disease at different stages versus controls, are presented, along with future applications of targeted validation of brain specific glycoproteins in body fluids.
Related Papers
- → Determination of glycosylation sites and site-specific heterogeneity in glycoproteins(2009)276 cited
- → Mass spectrometry-based N-glycoproteomics for cancer biomarker discovery(2014)59 cited
- → Glycoproteomics on the rise: Established methods, advanced techniques, sophisticated biological applications(2012)33 cited
- → Solutions to the Glycosylation Problem for Low- and High-Throughput Structural Glycoproteomics(2010)10 cited
- → Liquid Chromatography/Mass Spectrometry (LC/MS)-Based Glycoproteomics Technologies for Cancer Biomarker Discovery(2008)7 cited